United Therapeutics Corporation

December 9, 2015December 9, 2015

PAH Cell Therapy Shows Safety, Effectiveness in Phase 1 Study

News

Pluristem Therapeutics, Inc. has received notice from United Therapeutics Corp. ending its licensing agreement to develop PLX-PAD for the treatment of pulmonary arterial hypertension (PAH). According to a press release, Pluristem, ... Read more

June 22, 2015June 22, 2015

Mayo Clinic and United Therapeutics to Build Lung Restoration Center

News

The Mayo Clinic and United Therapeutics Corporation recently announced the establishment of a partnership focused on creating a new lung restoration center. The facility will be built on Mayo’s campus in Jacksonville, Florida ... Read more

September 10, 2014November 5, 2015

Safe Dosage Established For Experimental Pulmonary Arterial Hypertension Therapy

News, Pulmonary Hypertension

United Therapeutics Corporation, a licensee of Pluristem Therapeutics Inc., announced that investigators have finished establishing the safe dosage for an experimental PAH therapy in a phase I study for the first of the ... Read more